Allarity Therapeutics
- Country
- 🇺🇸United States
- Ownership
- Public
- Employees
- 6
- Market Cap
- -
- Website
- http://www.allarity.com
- Introduction
Allarity Therapeutics, Inc. engages in the development of drugs for personalized treatment of cancer guided by its proprietary Drug Response Predictor (DRP) technology. The company operates in two geographic areas: Denmark and the United States. The company was founded on April 4, 2021 and is headquartered in Boston, MA.
Study to Determine the Maximum Tolerated Dose (MTD) of PARPi 2X-121 Monotherapy and the MTD of Dovitinib in Combination With 2X-121 in Patients With Advanced Solid Tumors
- First Posted Date
- 2022-10-07
- Last Posted Date
- 2025-05-07
- Lead Sponsor
- Allarity Therapeutics
- Target Recruit Count
- 40
- Registration Number
- NCT05571969
- Locations
- 🇺🇸
Carolina BioOncology, Huntersville, North Carolina, United States
🇺🇸University Hospitals Cleveland Medical Center, Cleveland,, Ohio, United States
Anti-tumor Effect of Ixabepilone in Metastatic Breast Cancer (mBC) Selected by the Ixabepilone DRP.
- First Posted Date
- 2021-03-12
- Last Posted Date
- 2025-02-04
- Lead Sponsor
- Allarity Therapeutics
- Target Recruit Count
- 60
- Registration Number
- NCT04796324
- Locations
- 🇮🇹
Modena University Hospital, Modena, Italy
🇧🇪Antwerp University Hospital, Antwerp, Edegem, Belgium
🇧🇪Onze-Lieve-Vrouwziekenhuis, Aalst, Belgium
Investigation of the Anti-tumor Effect of 2X-121 in Patients With Recurrent, Advanced Ovarian Cancer
- First Posted Date
- 2019-03-18
- Last Posted Date
- 2025-05-08
- Lead Sponsor
- Allarity Therapeutics
- Target Recruit Count
- 40
- Registration Number
- NCT03878849
- Locations
- 🇺🇸
OU Health Stephenson Cancer, Oklahoma City, Oklahoma, United States
🇺🇸Swedish Center for Research and Innovation, Seattle, Washington, United States
Clinical Pre-screening Protocol for Ovarian Cancer
- Conditions
- Ovarian Cancer
- Interventions
- Device: Drug Response Predictor® (DRP)
- First Posted Date
- 2019-03-18
- Last Posted Date
- 2025-01-23
- Lead Sponsor
- Allarity Therapeutics
- Target Recruit Count
- 60
- Registration Number
- NCT03877796
- Locations
- 🇬🇧
Guy's and St Thomas' NHS Foundation Trust, Guy's Hospital, London, United Kingdom
🇺🇸Dana-Farber Cancer Institute, Boston, Massachusetts, United States
🇺🇸OU Health Stephenson Cancer Center, Oklahoma City, Oklahoma, United States
Irofulven in AR-targeted and Docetaxel-Pretreated mCRPC Patients With Drug Response Predictor (DRP®)
- Conditions
- Metastatic Castration-Resistant Prostate Cancer Patients
- Interventions
- Combination Product: Prednisolone 10 mg
- First Posted Date
- 2018-08-22
- Last Posted Date
- 2025-01-23
- Lead Sponsor
- Allarity Therapeutics
- Target Recruit Count
- 15
- Registration Number
- NCT03643107
- Locations
- 🇩🇰
Rigshospitalet, Dept. Of Oncology, Copenhagen, Denmark
Investigation of Anti-tumour Effect and Tolerability of the PARP Inhibitor 2X-121 in Patients With Metastatic Breast Cancer Selected by the 2X-121 DRP
- First Posted Date
- 2018-06-20
- Last Posted Date
- 2025-01-23
- Lead Sponsor
- Allarity Therapeutics
- Target Recruit Count
- 20
- Registration Number
- NCT03562832
- Locations
- 🇩🇰
Vejle Sygehus, Vejle, Denmark
🇩🇰Herlev and Gentofte Hospital, Herlev Ringvej 75, DK-2730 Herlev, Herlev, Denmark
Safety and Pharmacokinetics of Rising Doses of APO010 in Relapsed/Refractory Multiple Myeloma Patients Selected by DRP
- First Posted Date
- 2017-06-23
- Last Posted Date
- 2020-01-30
- Lead Sponsor
- Allarity Therapeutics
- Target Recruit Count
- 1
- Registration Number
- NCT03196947
- Locations
- 🇩🇰
University Hospital of Copenhagen, Copenhagen, Denmark
Phase I/II Study to Evaluate the Safety and Tolerability of LiPlaCis in Patients With Advanced or Refractory Tumours
- Conditions
- Phase 2 Part: Metastatic Breast Cancer, Prostate Cancer and Skin CancerPhase 1: Advanced or Refractory Solid Tumours
- Interventions
- First Posted Date
- 2013-05-23
- Last Posted Date
- 2022-02-24
- Lead Sponsor
- Allarity Therapeutics
- Target Recruit Count
- 50
- Registration Number
- NCT01861496
- Locations
- 🇩🇰
Vejle Sygehus, Vejle, Denmark
🇩🇰The Phase One Unit, The Finsen Centre, Rigshospitalet, Copenhagen, Denmark
🇩🇰Herlev & Gentofte Hospital, Herlev, Denmark